Behavioral and biochemical effects of a novel calcium antagonist, KB-2796, on the central dopaminergic system.
The effect of a novel calcium antagonist, KB-2796, on the central dopaminergic system was behaviorally and biochemically studied in mice and compared with that of flunarizine, nicardipine and chlorpromazine. Neither KB-2796 nor nicardipine had an inhibitory effect on apomorphine-induced cage climbing and turning behavior in mice with unilateral lesions in the striatum, even at a high dose of 100 mg/kg p.o. Both drugs slightly inhibited methamphetamine-induced increases in locomotor activity and turning behavior but only at a high dose (100 mg/kg p.o.). KB-2796 and nicardipine did not affect the content of dopamine (DA), norepinephrine, and serotonin, or the content of their metabolites homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC), and 5-hydroxyindoleacetic acid, or the DA turnover rate in the forebrain of mice. However, flunarizine and chlorpromazine inhibited behavioral changes induced by apomorphine or methamphetamine in a dose-dependent manner, increased the content of DOPAC and HVA and accelerated the DA turnover rate in mouse brain. These results suggest that KB-2796 has a negligible effect on the central dopaminergic system.